

Cheryl Baxter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5283480/publications.pdf>

Version: 2024-02-01

53
papers

5,551
citations

346980

22
h-index

206121

51
g-index

53
all docs

53
docs citations

53
times ranked

5778
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19: Impact on the HIV and Tuberculosis Response, Service Delivery, and Research in South Africa. <i>Current HIV/AIDS Reports</i> , 2022, 19, 46-53.	1.1	26
2	Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis. <i>Antiviral Therapy</i> , 2022, 27, 135965352110675.	0.6	1
3	Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. <i>Nature Medicine</i> , 2022, 28, 1785-1790.	15.2	456
4	Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review. <i>Journal of Infectious Diseases</i> , 2021, 223, 370-380.	1.9	50
5	Identifying SARS-CoV-2 infections in South Africa: Balancing public health imperatives with saving lives. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 221-225.	1.0	12
6	Recent Semen Exposure Impacts the Cytokine Response and Bacterial Vaginosis in Women. <i>Frontiers in Immunology</i> , 2021, 12, 695201.	2.2	7
7	The use of PSA as a biomarker of recent semen exposure in female reproductive health studies. <i>Journal of Reproductive Immunology</i> , 2021, 148, 103381.	0.8	0
8	COVID-19 in Africa: Catalyzing change for sustainable development. <i>PLoS Medicine</i> , 2021, 18, e1003869.	3.9	2
9	Higher mucosal antibody concentrations in women with genital tract inflammation. <i>Scientific Reports</i> , 2021, 11, 23514.	1.6	3
10	Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women. <i>Frontiers in Immunology</i> , 2020, 11, 1274.	2.2	1
11	Seroprevalence of hepatitis B virus: Findings from a population-based household survey in KwaZulu-Natal, South Africa. <i>International Journal of Infectious Diseases</i> , 2019, 85, 150-157.	1.5	17
12	Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis. <i>Viruses</i> , 2019, 11, 569.	1.5	2
13	Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial. <i>BMJ Open</i> , 2019, 9, e030283.	0.8	12
14	HIV incidence rates in adolescent girls and young women in sub-Saharan Africa. <i>The Lancet Global Health</i> , 2019, 7, e1470-e1471.	2.9	71
15	Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial. <i>Journal of the International AIDS Society</i> , 2019, 22, e25381.	1.2	13
16	Trends in HIV Prevention, Treatment, and Incidence in a Hyperendemic Area of KwaZulu-Natal, South Africa. <i>JAMA Network Open</i> , 2019, 2, e1914378.	2.8	33
17	Mechanisms of sexually transmitted infection-induced inflammation in women: implications for HIV risk. <i>Journal of the International AIDS Society</i> , 2019, 22, e25346.	1.2	45
18	The genital tract and rectal microbiomes: their role in HIV susceptibility and prevention in women. <i>Journal of the International AIDS Society</i> , 2019, 22, e25300.	1.2	43

#	ARTICLE	IF	CITATIONS
19	Semen IgM, IgG1, and IgG3 Differentially Associate With Pro-Inflammatory Cytokines in HIV-Infected Men. <i>Frontiers in Immunology</i> , 2019, 9, 3141.	2.2	5
20	HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition. <i>Nature Communications</i> , 2019, 10, 5227.	5.8	40
21	The microbiome and HIV prevention strategies in women. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 81-87.	1.5	16
22	Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study. <i>Lancet HIV</i> , 2017, 4, e41-e50.	2.1	220
23	Prevention of HIV in Adolescent Girls and Young Women: Key to an AIDS-Free Generation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, S17-S26.	0.9	80
24	Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials. <i>Antiviral Therapy</i> , 2016, 22, 287-293.	0.6	2
25	Combination HIV prevention options for young women in Africa. <i>African Journal of AIDS Research</i> , 2016, 15, 109-121.	0.3	39
26	Antibodies for HIV prevention in young women. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 183-189.	1.5	9
27	Improving adolescent maternal health. <i>South African Medical Journal</i> , 2015, 105, 948.	0.2	6
28	Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 530-539.	13.9	80
29	Genital Inflammation and the Risk of HIV Acquisition in Women. <i>Clinical Infectious Diseases</i> , 2015, 61, 260-269.	2.9	354
30	Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial. <i>Trials</i> , 2014, 15, 496.	0.7	9
31	Adherence in the CAPRISA 004 Tenofovir Gel Microbicide Trial. <i>AIDS and Behavior</i> , 2014, 18, 811-819.	1.4	21
32	Safety of Tenofovir Gel, a Vaginal Microbicide, in South African Women: Results of the Caprisa 004 Trial. <i>Antiviral Therapy</i> , 2013, 18, 301-310.	0.6	21
33	Microbicides for the prevention of sexually transmitted HIV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 12-23.	2.0	11
34	Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: Results from the CAPRISA 004 trial. <i>Antiviral Research</i> , 2013, 99, 405-408.	1.9	2
35	Microbicides for Prevention of HIV Infection: Clinical Efficacy Trials. <i>Current Topics in Microbiology and Immunology</i> , 2013, 383, 97-115.	0.7	10
36	When to start antiretroviral therapy during tuberculosis treatment?. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 35-42.	1.3	37

#	ARTICLE	IF	CITATIONS
37	Topical Microbicides—What's New?. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, S144-S149.	0.9	17
38	Symptomatic Vaginal Discharge Is a Poor Predictor of Sexually Transmitted Infections and Genital Tract Inflammation in High-Risk Women in South Africa. <i>Journal of Infectious Diseases</i> , 2012, 206, 6-14.	1.9	171
39	A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 695-715.	1.9	22
40	Overview of microbicides for the prevention of human immunodeficiency virus. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 427-439.	1.4	34
41	The Relationship Between Obesity and Complications After Neonatal Circumcision. <i>Journal of Urology</i> , 2011, 186, 1638-1641.	0.2	10
42	Contraceptive Choices, Pregnancy Rates, and Outcomes in a Microbicide Trial. <i>Obstetrics and Gynecology</i> , 2011, 118, 895-904.	1.2	32
43	Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. <i>Trials</i> , 2011, 12, 67.	0.7	33
44	Integration of Antiretroviral Therapy with Tuberculosis Treatment. <i>New England Journal of Medicine</i> , 2011, 365, 1492-1501.	13.9	451
45	The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. <i>South African Medical Journal</i> , 2010, 100, 808.	0.2	10
46	Preventing HIV Infection in Women: A Global Health Imperative. <i>Clinical Infectious Diseases</i> , 2010, 50, S122-S129.	2.9	97
47	Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. <i>Science</i> , 2010, 329, 1168-1174.	6.0	2,239
48	Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. <i>New England Journal of Medicine</i> , 2010, 362, 697-706.	13.9	608
49	PRO 2000: next steps for microbicide development. <i>Future Virology</i> , 2009, 4, 317-320.	0.9	2
50	Antiretroviral prophylaxis for the prevention of HIV infection: future implementation challenges. <i>HIV Therapy</i> , 2009, 3, 3-6.	0.6	29
51	Utilizing nucleic acid amplification to identify acute HIV infection. <i>Aids</i> , 2007, 21, 653-655.	1.0	11
52	Global Epidemiology of HIV-AIDS. <i>Infectious Disease Clinics of North America</i> , 2007, 21, 1-17.	1.9	24
53	Antiretroviral therapy: challenges and options in South Africa. <i>Lancet, The</i> , 2003, 362, 1499.	6.3	5